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Abstract
Background The andropause is associated with declines in serum testosterone (T), loss of muscle mass (sarcopenia), and frailty.
Two major interventions purported to offset sarcopenia are anabolic steroid therapies and resistance exercise training (RET).
Nonetheless, the efﬁcacy and physiological and molecular impacts of T therapy adjuvant to short-term RET remain poorly deﬁned.
Methods Eighteen non-hypogonadal healthy older men, 65–75 years, were assigned in a random double-blinded fashion
to receive, biweekly, either placebo (P, saline, n = 9) or T (Sustanon 250 mg, n = 9) injections over 6 week whole-body RET
(three sets of 8–10 repetitions at 80% one-repetition maximum). Subjects underwent dual-energy X-ray absorptiometry,
ultrasound of vastus lateralis (VL) muscle architecture, and knee extensor isometric muscle force tests; VL muscle biopsies
were taken to quantify myogenic/anabolic gene expression, anabolic signalling, muscle protein synthesis (D2O), and break-
down (extrapolated).
Results Testosterone adjuvant to RET augmented total fat-free mass (P=0.007), legs fat-free mass (P=0.02), and appendic-
ular fat-free mass (P=0.001) gains while decreasing total fat mass (P=0.02). Augmentations in VL muscle thickness, fascicle
length, and quadriceps cross-section area with RET occured to a greater extent in T (P < 0.05). Sum strength (P=0.0009)
and maximal voluntary contract (e.g. knee extension at 70°) (P=0.002) increased signiﬁcantly more in the T group. Mecha-
nistically, both muscle protein synthesis rates (T: 2.13 ± 0.21%·day1 vs. P: 1.34 ± 0.13%·day1, P=0.0009) and absolute
breakdown rates (T: 140.2 ± 15.8 g·day1 vs. P: 90.2 ± 11.7 g·day1, P=0.02) were elevated with T therapy, which led to
higher net turnover and protein accretion in the T group (T: 8.3 ± 1.4 g·day1 vs. P: 1.9 ± 1.2 g·day1, P=0.004). Increases
in ribosomal biogenesis (RNA:DNA ratio); mRNA expression relating to T metabolism (androgen receptor: 1.4-fold; Srd5a1:
1.6-fold; AKR1C3: 2.1-fold; and HSD17β3: two-fold); insulin-like growth factor (IGF)-1 signalling [IGF-1Ea (3.5-fold) and IGF-
1Ec (three-fold)] and myogenic regulatory factors; and the activity of anabolic signalling (e.g. mTOR, AKT, and RPS6; P <
0.05) were all up-regulated with T therapy. Only T up-regulated mitochondrial citrate synthase activity (P=0.03) and tran-
scription factor A (1.41 ± 0.2-fold, P=0.0002), in addition to peroxisome proliferator-activated receptor-γ co-activator 1-α
mRNA (1.19 ± 0.21-fold, P=0.037).
Conclusions Administration of T adjuvant to RET enhanced skeletal muscle mass and performance, while up-regulating myo-
genic gene programming, myocellular translational efﬁciency and capacity, collectively resulting in higher protein turnover,
and net protein accretion. T coupled with RET is an effective short-term intervention to improve muscle mass/function in older
non-hypogonadal men.
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Introduction
Age-related declines in muscle mass and strength
(sarcopenia)1 are associated with mitochondrial abnormali-
ties,2 fatigue, lack of energy, loss of libido, decreased sexual
performance,3 and work capacity.4 Many of these symptoms
are accompanied by declines in testosterone (T) bioavailabil-
ity—the ‘andropause’.5 Moreover, hypogonadal men exhibit
a three-fold increase in mortality and a ﬁve-fold increased risk
of cancer-related deaths.6 Thus, as the ageing populace
grows, there remains a need for therapies to counteract the
andropause and associated muscle wasting and dysfunction.
Clinically, older men with a total T of <231 ng·dL1 may be
offered T therapy6 due to established positive effects on fat-
free mass (FFM),7 fat mass,8 muscle function,5 and mitochon-
drial biogenesis.9 Intramuscular T injections offer a safer,
more efﬁcacious treatment than oral or transdermal T.6 In-
deed, dose-dependent increases in type I and type II ﬁbre
areas were found in relation to T injection titrations (25–
600 mg·week1) in men >65 years.10 In addition, 6 month
T injection (~210 mg biweekly) enhanced net protein bal-
ance,5 myoﬁbrillar protein synthesis (MPS),11 FFM,5,11 and
muscular performance5 (albeit through ill-deﬁned mecha-
nisms). However, the therapeutic efﬁcacy of T injection in
older men remains controversial and, likely, non-beneﬁcial
with short-term physiological dosing (at least in the absence
of co-existing countermeasures). For example, ≤6 week T
therapy did not improve MPS, RNA content,12 FFM (transder-
mal 50 mg·day1),13 or strength (200 mg biweekly for 12
weeks).14,15 Besides administering longer-term pharmacolog-
ical doses of exogenous T, interventions that boost endoge-
nous sex hormones, that is, exercise, might be of greater
beneﬁt.16
In relation to strategies to overcome age-related muscle
dysfunction, the effects of resistance exercise training (RET)
on skeletal muscle are well deﬁned. RET promotes muscle
anabolism (even in old age17,18) and stimulates mitochondrial
adaptations2; these effects are also associated with enhanced
endogenous T in response to acute bouts of RE.19 Nonethe-
less, hypertrophic responses to RET are blunted in older age
(vs. younger cohorts), so-called anabolic resistance, suggest-
ing the need for strategies beyond, or adjuvant to RET,19 in
order to maximize efﬁcacy. We previously showed that acute
RET-induced systemic induction of endogenous T was related
to ensuing muscle hypertrophy in younger men,20 suggesting
a link between T and muscle mass gains with RET. Moreover,
in keeping with a role for T as an adjuvant therapy to RET in
older age, 50–100 mg·day1 transdermal T therapy enhanced
RET-induced muscle mass gains over 12 weeks,21 while supra-
physiological doses (600 mg·week1) of T adjuvant to RET for
10 weeks increased FFM and strength (in younger men (19–
40 years).22 Such ‘medium-term’ use of T therapy is indicated
for minimizing side effects23 of longer-term T therapy, for ex-
ample, ≥24 weeks,24 and may be useful for pre-habilitation/
rehabilitation (e.g. from bed-rest). That said, RET interven-
tions of ~12 weeks still engender a major time burden from
the perspective of physiotherapy and engender minimal
anthropometrical beneﬁts in the absence of adjuvant ther-
apy, even after 24 weeks in older men.21
We have previously shown that the majority of muscle
mass gains with RET occur early into RET,20,25,26 albeit that
this is blunted in older individuals. Therefore, in an effort to
identify a more time-efﬁcient and clinically efﬁcient strategy
of T therapy and to determine the mechanisms of T therapy
adjuvant to RET in relation to anabolic resistance, we investi-
gated the efﬁcacy and cellular mechanisms of short-term RET,
coupled to adjuvant T therapy in older men. In a double-blind
investigation into the effects of 6 weeks of RET with or with-
out T therapy, we determined end-points relating to muscle
mass, function, myogenic regulation, anabolic signalling, and
protein turnover.
Methods
Study ethics and participants
This study was approved by the University of Nottingham,
Faculty of Medicine and Health Sciences Research Ethics
Committee (G11082015 SoMS MSGEM), was conducted ac-
cording to the Declaration of Helsinki, and was pre-registered
at clinicaltrials.gov (NCT02152839). Before entry into the
study, participants provided written informed consent to par-
ticipate after all procedures and risks were explained to
them. All participants performed activities of daily living and
were recreationally active but had not partaken in RET within
the previous 12 months. Participants were screened by med-
ical questionnaire, physical examination, routine blood chem-
istry, and a resting electrocardiogram. Participants who
presented with metabolic, respiratory, or cardiovascular dis-
orders or who were prescribed medication (e.g. beta-
adrenergic blocking agents, statins, and anti-inﬂammatory
drugs) and any other medications that could inﬂuence T me-
tabolism were excluded. Of the screened participants, 18
non-hypogonadal, healthy, normotensive (<140/90) older
men with morning serum T concentrations of >230 ng·dL1
(suggested threshold of the lower range of normal T to
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diagnose hypogonadism27) were assigned in a random
double-blinded fashion to receive biweekly injections of ei-
ther placebo (P, saline n = 9, serum T level) or T (Sustanon
250 mg, n = 9) (gold standard dosing28) over ~6 weeks of
whole-body fully supervised RET. All participants involved in
the study were monitored throughout the study for any neg-
ative side effects of T injections. No adverse events were re-
ported during or after completion of the study.
Study conduct
Following baseline measurements of maximal voluntary con-
traction (MVC) and one-repetition maximum (1-RM; on sepa-
rate days), regardless of group assignment, all participants
were further characterized at baseline. This involved collec-
tion of fasting blood sampling, muscle ultrasound (Mylab
70; Esaote Biomedica, Italy) of the m. vastus lateralis muscle
(VL), and a dual-energy X-ray absorptiometry (DXA; Lunar
Prodigy II, GE Medical Systems, Little Chalfont, UK) scan. Fi-
nally, a unilateral muscle biopsy was taken under rested con-
ditions from the VL (Figure 1, baseline i.e. Wk -1). Given the
moderately short half-life of T (i.e. 4–5 days29), it was admin-
istered every two-weeks, and subsequent biopsies were
taken at week 0, 1.5, 3, and 6 which were 7, 2, 14, and 7 days
after corresponding biweekly T injections, respectively. In or-
der to assess rates of MPS, a basal saliva sample was col-
lected before the muscle biopsy, and the ﬁrst dose of D2O
as a bolus of 3 mL·kg1 body weight was consumed by partic-
ipants after the biopsy. The initial priming dose of D2O was
followed by daily small-volume ‘top-ups’ of ~20 mL
(calculated from measures of each individual’s body water
pool turnover). Finally, an injection of T or P was adminis-
tered by an unblinded clinical research technician. The fully
supervised RET protocol then commenced and continued
for the next 6 weeks. Additional VL biopsies (60 min after
bouts of RE to obtain temporal acute effects of RE across
training) and other tests/samples took place intermittently
during these 6 weeks (Figure 1). All muscle samples were col-
lected under sterile conditions, using the conchotome biopsy
technique30 with 1% w/v lidocaine as local anaesthetic. Any
fat tissue and connective tissue was rapidly dissected out,
and muscle was washed in ice-cold phosphate-buffered saline
and frozen in liquid nitrogen or liquid nitrogen-cooled
isopentane, before storage at 80 °C. Participants were pro-
vided 10 mg (D3-methyl)–3-methylhistidine (3MH) in 100 mL
water on three occasions during the study and returned to
the research unit (fasted) after 21 h for blood sampling every
2 h (i.e. at 21, 23, and 25 h after 3MH ingestion). A detailed
schematic of the study protocol is depicted in Figure 1.
Resistance training procedures and strength
assessments
Participants in both groups performed the same whole-body
RET including leg extension, leg press, leg curl, lat pull-down,
shoulder-press, and bench press (all three sets of 8–10
repetitions at 80% 1-RM)31 three times per week non-
consecutively for 6 weeks. Individuals’ 1-RM32 was re-
assessed every 2 weeks before the corresponding training
session to maintain intensity with progression. An isokinetic
Figure 1 Schematic diagram of the study protocol. 1-RM, one-repetition maximum; 3MH, 3-methylhistidine; DXA, dual-energy X-ray absorptiometry;
RET, resistance exercise training.
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dynamometer (Isocom; Isokinetic Technologies, Eurokinetics,
UK) was used to assess isometric knee extensor torque during
MVC using two knee joint angles (70 and 80°), with full exten-
sion corresponding to 0°. Each individual muscle contraction
lasted 4 s, with 30 s rest between contractions and 90 s be-
tween knee joint angle assessments. In addition, speciﬁc
strength (MVC 70°·per LM) was calculated as MVC at 70° di-
vided by leg FFM (LM).
Muscle architecture by ultrasound and dual-energy
X-ray absorptiometry-derived muscle mass
Every 10 days and immediately before corresponding training
session, B-mode ultrasonography (Mylab 70, Esaote
Biomedica) with a 100 mm, 10–15 MHz, linear array probe
was used for quantiﬁcation of myo-architecture. Images were
obtained at 50% of the VL length and the mid-sagittal line
while the participant was lying supine on a couch.33 To assess
fascicle length (Lf), the transducer was aligned with the fasci-
cles to facilitate optimal image capture of the fascicles. The
intersection between fascicles and deep tendon aponeurosis
and the perpendicular distance between the superﬁcial and
deep tendon aponeurosis were used to assess pennation
angle (PA) and muscle thickness (MT).34 Finally, extended
ﬁeld-of-view ultrasonography was used to quantify the
cross-sectional area (CSA) of the quadriceps.35 ImageJ soft-
ware (ImageJ 1.51h) was used to analyse the images.
Before and after the study, DXA (64752, GE Medical
Systems-Lunar Prodigy, USA) was used to determine total
FFM, LM, total fat percentage, total fat mass, FFM index
(FFM divided by height squared (FFM·height2)), and appen-
dicular FFM (FFM of arms and legs in kilograms divided by
square of height in metres). Participants were asked to
attend overnight fasting having not performed any heavy
physical activity 24 h prior to scanning. For the DXA scan,
participants wore loose comfortable clothing with no metal
or plastic zippers, buttons, or snaps. Prior to use on partici-
pants, a QA block phantom was used to calibrate the system,
to ensure optimal measurement. In addition, spine phantoms
were run bimonthly to assess the reproducibility and accu-
racy of the system over time.
Testosterone enzyme-linked immunosorbent assay
Venous blood samples were collected into EDTA-coated tubes
intermittently during the study, that is, before injections and
prior to individual resistance exercise sessions in the morn-
ings to measure ﬂuctuations in total T concentrations. Blood
samples were immediately cold centrifuged at 1750 g, with
resulting plasma fractions aliquoted and frozen at –80 °C until
further analysis. An enzyme-linked immunosorbent assay
(ab108666, Abcam, UK) competitive technique was used to
assess the abundance of total T in the plasma of all partici-
pants The intra-assay coefﬁcient of variation was <5%, and
the assay sensitivity was 70 ng·dL1; the detection range
was 20–1600 ng·dL1.
Muscle immunohistochemistry
Serial 5-μm-thick VL muscle cross-sections were cut at 20 °C
using a cryostat (Leica, CM 1850, Germany), mounted on
glass slides, and air dried at room temperature. Determina-
tion of ﬁbre-type-speciﬁc cross-sectional area was performed
using monoclonal antibodies against slow (BA-F8) and fast
myosin (SC-71) and laminin (D18) (Developmental Studies Hy-
bridoma Bank). Visualization of the primary antibodies was
achieved by incubation with Alexa Fluor 488 and 568 goat
anti-mouse secondary antibodies (Invitrogen A/S) in situ.
Muscle sections were then mounted with Molecular Probes
Prolong Gold antifade reagent (Invitrogen A/S). Three major
ﬁbre types (I, IIA, and IIX) were determined as previously de-
scribed.36 Fibre area was measured using Sigma Scan Pro 5
software.
Body water and protein-bound alanine muscle
protein synthesis
To determine the exact volume of D2O to be consumed for
daily ‘top-ups’, each participant provided saliva for the ﬁrst
3 days after initial D2O consumption. These were processed
to determine each participant’s body water decay rate, and
from this, the amount of D2O needed to maintain a steady
state over the study period could be calculated. Individuals
were then provided with stocks of daily D2O ‘top-ups’
(~10% initial bolus dose) with thrice weekly saliva collection
for rest of the study period. Wilkinson et al.37 previously de-
scribed how body water and muscle protein enrichment were
analysed. Brieﬂy, 80–90 μL of saliva was heated in inverted 2
mL autosampler vials for 4 h at 90–100 °C to purify fractions
of the body water. The vials were then cooled on ice and be-
fore the condensed body water was transferred to a clean
autosampler vial for injection. A high-temperature conversion
elemental analyser (Thermo Finnigan, Thermo Scientiﬁc,
Hemel Hempstead, UK) connected to an isotope ratio mass
spectrometer (Delta V advantage, Thermo Scientiﬁc) was
employed to measure deuterium labelling in saliva (0.1 μL).
To assess protein-bound alanine muscle fraction enrichment,
~40 mg of muscle was homogenized in ice-cold homogeniza-
tion buffer to isolate myoﬁbrillar proteins.20 Brieﬂy, 10 min
rotary mixing was followed by centrifugation at 11 000 g for
15 min at 4 °C, the supernatant (sarcoplasmic fraction) was
then collected for immunoblotting, and the pellet was resus-
pended in 500 μL mitochondrial extraction buffer (MEB) and
then homogenized by Dounce and centrifuged at 1000 g for 5
4 N. Gharahdaghi et al.
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12472
min at 4 °C. Insoluble collagen was separated following centri-
fugation from myoﬁbrillar proteins that were solubilized in
750 μL NaOH and subsequently precipitated using 1 M
perchloric acid (PCA) then pelleted by centrifugation. Follow-
ing overnight hydrolysis at 110 °C in a 0.1 M HCl and Dowex
H+ resin slurry, the amino acids were eluted with 2 M NH4OH
and dried down. Dried samples were suspended in 60 μL
distilled water, 32 μL methanol, and 10 μL pyridine and 8
μL methyl chloroformate with intermittent vortex. The
n-methoxycarbonyl methyl esters of the amino acids were
then extracted after adding 100 μL chloroform. A
molecular sieve was added to remove water for ~20 s before
being transferred to vials; incorporation of deuterium
into the protein-bound alanine was determined by gas
chromatography–pyrolysis–isotope ratio mass spectrometry
(Delta V Advantage, Thermo, Hemel Hempstead, UK).20
Calculation of synthetic fractional rate
MPS was calculated from the deuterium enrichment (APE) in
alanine in myoﬁbrillar proteins, using the body water enrich-
ment (APE, corrected for the mean number of deuterium
moieties incorporated per alanine, 3.7, and the dilution from
the total number of hydrogens in the derivative, i.e. 11) as
the precursor labelling between subsequent biopsies. The
fractional synthetic rate (FSR) was calculated as follows:
FSR %day1  ¼ In
1 ðAPEAlaAPEP
h i
t
2
4
3
5;
where APEAla is deuterium enrichment of protein-bound ala-
nine, APEP is mean precursor enrichment of the body water
over the period, and t is the time between biopsies. Absolute
synthetic rate (ASR) was estimated as follows:
ASR gday1  ¼ FSR
100
TotalFFM 12:4
100
;
where alkali-soluble protein of 12.4% total FFM was
assumed.38 Absolute protein breakdown rate (ABR) was esti-
mated as follows:
ABR gday1  ¼ FBR
100
Total FFM 12:4
100
;
where fractional breakdown rate (FBR) is calculated as FBR =
FSR  FGR, with the fractional growth rate (FGR) assumed to
be % FFM gain per day over 7 weeks derived by DXA. In addi-
tion, the net protein turnover was calculated as follows: ASR
 ABR.
Muscle protein breakdown measures using D3–3-
methylhistidine
Precisely, 100 μL of plasma was aliquoted and deproteinized
in 1 mL of ice-cold acetonitrile:methanol (1:1). Following ~1
h of cooling at 20 °C, samples were centrifuged at 17 000
g for 20 min at 4 °C. The resulting supernatant was dried
and resuspended in 100 μL acetonitrile: ddH2O (1:1). Follow-
ing centrifugation at 17 000 g, samples were transferred to
autosampler vials for the determination of D3–3MH enrich-
ment by liquid chromatography–mass spectrometry (on a Q
Exactive Orbitrap, Thermo Hemel Hempstead, UK). The en-
richment decay curves were log transformed to determine
the decay constant (k), which represents the fractional rate
of muscle protein breakdown (MPB).39
Muscle RNA, DNA, and protein content
Approximately 15 mg wet weight muscle was used to deter-
mine alkaline-soluble protein (ASP), RNA, and DNA content.
Initially, 0.2 M PCA was used to homogenize tissue, followed
by centrifugation at 11 680 g. Pellets were re-solubilized in
0.3 M NaOH, and protein contents were quantiﬁed by
spectrophotometry (NanoDrop Lite, Thermo Scientiﬁc).
Thereafter, the resulting supernatant was used for RNA quan-
tiﬁcation at 260 nm by spectrophotometry; the pellet was
then heated at 70 °C for 1 h in 2 M PCA to extract the DNA
and centrifuged, and DNA was quantiﬁed at 268 nm by
spectrophotometry.20
Immunoblotting for anabolic/catabolic signalling
Spectrophotometry was used to determine protein concen-
trations of sarcoplasmic fractions, and samples were diluted
with 3× Laemmli loading buffer to 1 mg·mL1, followed by
heating at 95 °C for 5 min. Precisely, 10 μg of sample was
loaded onto Criterion XT Bis–Tris–12% SDS-PAGE gels (Bio-
Rad) for electrophoresis at 185 V for 45 min. After electro-
phoresis, as previously described,40 samples were transferred
onto polyvinylidene diﬂuoride membranes for 45 min at 100
V. Subsequently, 2.5% low-fat milk, which was diluted in
Tris-buffered saline Tween 20 (TBST), was used to soak and
block polyvinylidene diﬂuoride membranes for 1 h at ambient
temperature and then incubated in the following primary
antibodies overnight at 4 °C (1:2000 dilution in 2.5% bovine
serum albumin in TBST): rabbit phospho-protein kinase B
(Akt)Ser473 (#9271), phospho-mechanistic target of rapamycin
(mTOR)Ser2448 (#2971), phospho-mitogen-activated protein
kinase (MEK1/2)Ser217/221 (#9121), phospho-MAP kinase-
activated protein kinase 2 (MAPKAPK-2)Thr334 (#3007),
phospho-ribosomal protein S6 (RPS6)ser235/236 (#2211),
phospho-AMP-activated protein kinase (AMPKα)Thr172
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(#2531), phospho-regulatory-associated protein of mTOR
(Raptor)Ser792 (#2083), phospho-forkhead box O3
(FOXO3a)Ser253 (#13129) (all from Cell Signaling Technology,
Leiden, The Netherlands), muscle-speciﬁc F-box protein
(MAFbx) (#AP2041), muscle RING-ﬁnger protein-1 (MURF-1)
(#101AP) (both from ECM Biosciences, Versailles, KY, USA),
and mouse oxidative phosphorylation (OxPhos) (Abcam, Cam-
bridge, MA, USA). After overnight incubation, membranes
were washed 3 × 5min in TBST and soaked in horseradish per-
oxidase (HRP)-conjugated secondary antibody (New England
Biolabs; 1:2000 in 2.5% bovine serum albumin in TBST) for 1
h, before 3 × 5 min washes in TBST. In order to quantify band
intensity (Chemidoc MP, Bio-Rad, Hemel Hempstead, UK),
membranes were exposed to Chemiluminescent HRP sub-
strate (Millipore Corp., Billerica, MA, USA) for 5 min. Relative
arbitrary units were normalized to Coomassie-stained mem-
branes and to cross gel loading control.
Gene expression analysis of myogenesis,
insulin-like growth factor-1 related, and
testosterone processing
Approximately 10 mg of muscle was homogenized, with one
stainless steel bead (Tissue Lyser II, Qiagen, UK), for 2 min at
frequency of 30 s1 in 500 μL TRIzol (Life
Technologies/Thermo Fisher Scientiﬁc) to isolate total RNA ac-
cording to the manufacturer’s instructions. A high-capacity
cDNA reverse transcription kit (Life Technologies) was used to
reverse transcribe 500 ng of total RNA for quantitative reverse
transcription PCR. Precisely, 1 μL of 1:10 diluted cDNA was
added in each well of 384 optical well plates (Life Technologies).
Exon–exon boundary speciﬁc primers were mixed with SYBR
Select Master Mix (Life Technologies), and RNase-free water
and 6 μL of the mixed solution, as well as 1 μL of each cDNA,
were added to each well, with samples run in triplicate. The
ViiATM 7 Real-Time PCR System (Life Technologies) was used
according to the following thermal cycling conditions: 2 min
at 50 °C, 2 min at 95 °C, and 40 cycles of 15 s at 95 °C and 60
s at 60 °C. The ΔΔCt method was used to quantify target mRNA
expression with peptidylprolylisomerase A levels measured to
correct for variations in RNA input/cDNA synthesis.41 Primer se-
quences for each of the probed genes are listed in Table 1.
Mitochondrial citrate synthase activity and DNA
copy number
Citrate synthase (CS) activity was measured as described.42
Brieﬂy, after homogenization of 3–5 mg muscle in 1% Triton
X-100 buffer, samples were centrifuged at 22 000 g for 3
min, and the supernatant was used for further analysis. There-
after, 300 μL Master Mix containing 28% 0.05 M Tris buffer
(pH 7.6), 1.3% 1 mM 5,5′-dithiobis-2-nitrobenzoic acid, 7%
acetyl-coenzyme A (1.36 mg·mL1), 0.8% oxaloacetate (9.88
mg·mL1), and 63% ddH2O was measured at 412 nm as the
blank. Finally, 20 μL of separated supernatant was used to
measure the maximum rate of reaction (Vmax), compared with
whole protein content. To quantify relative mitochondrial
DNA (mtDNA) copy number, the extraction of genomic and
mtDNA from muscle was performed using a Qiagen QIAamp®
DNA Mini Kit, according to the manufacturer’s recommenda-
tions. Brieﬂy, the procedure involved tissue lysis in a protein-
ase K buffer, incubation for 3 h at 56 °C to digest myoﬁbrils
followed by centrifugation of the lysates through silica
membrane-based nucleic acid puriﬁcation columns and
Table 1 Primer sequences used in PCR
Forward Reverse
RPL13A 5′-TAAACAGGTACTGCTGGGCCG-3′ 5′-CTCGGGAAGGGTTGGTGTTC-3′
AR 5′-GGTGAGCAGAGTGCCCTATC-3′ 5′-GCAGTCTCCAAACGCATGTC-3′
SRD5A1 5′-TACGGGCATCGGTGCTTAAT-3′ 5′-AATCGCCATTGTACACGCCA-3′
AKR1C3 5′-GGAGAAGCAGCAGCAAACATT-3′ 5′-CTTTACTTCTCGGAACCTCTGGA-3′
HSD17B3 5′-TGTACTCAGCTTCCAAGGCG-3′ 5′-TATGGGGTCAGCACCTGGAT-3′
IGF-1Ea 5′-TCAAATGTACTTCCTTCTGGGTC-3′ 5′-TAAGGAGGCTGGAGATGTATTGC -3′
IGF-1Ec 5′-AAATCAGCAGTCTTCCAACCC-3′ 5′-GTGTGCATCTTCACCTTCAAGAAA-3′
MHC1 5′-ATCTCTACGCCAGGGTCCTTA-3′ 5′-TTTCGGAGGAAAGGAGCAGC-3′
MHCIIa 5′-GCCCTTGGAATGAGGCTGAC-3′ 5′-TGCTGAACTCAGAGGTCCTTGTT-3′
Myogenin 5′-CCAGGGGATCATCTGCTCACG-3′ 5′-GGTTTCATCTGGGAAGGCCA-3′
Myf-6 5′-CAAGAAAATCTTGAGGGTGCGG-3′ 5′-TTAGCCGTTATCACGAGCCC-3′
C-Myc 5′-AACCACCACCATCCCTGTTTG-3′ 5′-AAGGCCCCCAGACCCATTTC-3′
MEOX-2 5′-TGAAAGACAGGTGAAAGTCTGG-3′ 5′-ACCAGTTCCTTTTCCCGAGC-3′
C-met 5′-ACAGCTGACTTGCTGAGAGG-3′ 5′-AGGTTTATCTTTCGGTGCCCA-3′
PAX7 5′-CGGCCAGACTGCTGTTGATTAT-3′ 5′-GAGTCCCAGCACAGCAGAGT-3′
PGC1-α 5′-GAGTCATACTTGCTCTTGGTG-3′ 5′-GATGATGGAGACAGCTATGGT-3′
Tfam 5′-TTCGTCCTCTTTAGCATGCTGA-3′ 5′-CACCGCAGGAAAAGCTGAAG-3′
AKR1C3, aldo-keto reductase family 1 member C3; AR, androgen receptor; C-met, met proto-oncogene, receptor tyrosine kinase;
HSD17B3, hydroxysteroid 17-β dehydrogenase 3; IGF-1, insulin-like growth factor-1; MEOX-2, mesenchyme homeobox 2; MHC, myosin
heavy chain;Myf-6, myogenic factor 6; C-Myc, MYC proto-oncogene, BHLH transcription factor; PAX7, paired box 7; PGC1-α, peroxisome
proliferator-activated receptor-γ co-activator 1-α; RPL13A, ribosomal protein L13A; SRD5A1, steroid 5 α-reductase 1; Tfam, mitochondrial
transcription factor A.
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subsequent elution of the mtDNA and gDNA. The quality and
quantity of DNA was assessed by measurement at 260, 280,
and 230 nm. The expression level of markers of gDNA and
mtDNA used to evaluate their abundance was accomplished
by using TaqMan probe real-time PCR. The TaqMan probe de-
sign for the detection of gDNA levels was based on interroga-
tion of the intron sequence spanning between exons 3 and 4
of the genomic hydroxymethylbilane synthase (HMBS) gene
to avoid mRNA ampliﬁcation. The probe design for detection
of mtDNA levels was based on interrogation of a stable frag-
ment of the mtDNA loop, namely, the mitochondrially
encoded NADH:ubiquinone oxidoreductase core subunit 1
(ND1). The 2ΔCt formula, where Δ = CtND1  CtHMBS, was
used to express relative mtDNA copy number.
Statistical analyses
Data are expressed as mean ± standard error of the mean,
while normality of distribution was examined using the
Kolmogorov–Smirnov test. In addition, analysis of covariance
using baseline values for each outcome as a covariate and re-
peated measures analysis of variance (time) with one
between-subject factor (group) were used to compare the
changes during the RET programme both within and between
the two (P vs. T) groups. In addition, independent t-tests were
used for comparing fold change between the two groups.
Cohen’s effect sizes (ES) were also calculated for signiﬁcant
data. ES of 0 to <0.20 were considered ‘trivial’, 0.20 to <0.50
were considered ‘small’ in magnitude, 0.50 to<0.80were con-
sidered ‘medium’, and ≥0.80 were considered ‘large’.43 Where
signiﬁcant differences were found using repeated measures
analysis of variance, a Bonferroni post hoc test was applied
for multiple comparisons. The correlation was assessed using
Pearson’s product moment correlation coefﬁcient and
intraclass correlation coefﬁcient (ICC) was used to test reliabil-
ity of DXA and ultrasound-related outputs. The signiﬁcance
level was deﬁned as P ≤ 0.05, and all of the statistical analyses
were performed using GraphPad Prism 7.01 (La Jolla, CA, USA).
Results
Physiological characteristics of participants are shown in Table
2. In accordance, only the T study group signiﬁcantly
increased weight (P=0.006, 95% conﬁdence interval (CI) = 81–
83, ES = 0.19) and body mass index (P=0.006, 95% CI = 26–
26.6) after 6 weeks of RET, primarily through signiﬁcant gains
in FFM in the T group vs. baseline (see the Body composition
section). Further, total plasma T concentrations in the T therapy
group were signiﬁcantly higher than in the P group at all time-
points after baseline (P < 0.05), that is, 234.9 ± 7 ng·dL1 at
baseline, and achieved 973 ± 54 at 0 week and 1149 ± 75
ng·dL1 after 5weeks in T group (95% CI = 1044–1232). Plasma
T concentrations during the study are shown in Figure 2.
Body composition
Total FFM (ICC = 0.94) increased signiﬁcantly following 6
week RET in T (53.0 ± 1.7 to 56.0 ± 5.2 kg, P=0.007, 95% CI
= 55.5–57.6, ES = 0.45, Figure 3A) but not in P (54.1 ± 6.3
to 54.8 ± 5.8 kg, 95% CI = 53.2–55.4). Likewise, only T aug-
mented LM (17.2 ± 0.7 to 18.1 ± 0.8 kg, 95% CI = 17.8–18.6
vs. 17.4 ± 0.8 to 17.6 ± 0.7 kg, 95% CI = 17.1–17.9, P=0.02,
ES = 0.30, ICC = 0.96, Figure 3B), appendicular FFM (7.8 ±
0.3 to 8.3 ± 0.3, 95% CI = 8.2–8.5 vs. 7.9 ± 0.3 to 8.0 ± 0.3,
95% CI = 7.7–8.1, P=001, ES = 0.54, ICC = 0.94, Figure 3D),
and FFM index (17.2 ± 0.4 to 18.2 ± 0.4 kg·m2, 95% CI =
18.1–18.7 vs. 17.5 ± 0.6 to 17.8 ± 0.5 kg·m2, 95% CI =
17.3–18.1, P=0.005, ES = 0.42, ICC = 0.92, Figure 3C) after
RET. In addition, both total fat percentage (29.7 ± 1.7 to
27.5 ± 1.4%, 95% CI = 27–28.8 vs. 30.6 to 30.2%, 95% CI =
29–30.7, P=0.004, ICC = 0.96, ES = 0.43) and total fat mass
(22.5 ± 2.0 to 21.3 ± 1.8 kg, 95% CI = 21.6–23.1 vs. 24.7 ±
2.8 to 24.5 ± 2.7 kg, 95% CI = 22.8–24.2, P=0.02, ICC = 0.97,
ES = 0.29) decreased signiﬁcantly in T but not in P (Figure
3E and 3F).
Muscle architecture
Over the RET period, T and P both exhibited increases in MT
(2.3 ± 0.07 to 2.6 ± 0.04 cm, 95% CI = 2.5–2.6, P < 0.0001, ES
= 0.83 vs. 2.3 ± 0.1 to 2.4 ± 0.09 cm, 95% CI = 2.4–2.5, P <
Table 2 Participant characteristics
T (n = 9) P (n = 9)
Baseline Week 6 Baseline Week 6
Age (years) 69.7 (0.8) –– 69.5 (1.3) ––
Height (m) 1.75 (0.02) –– 1.76 (0.02) ––
Weight (kg) 78.6 (3.1) 80.4 (3.2)a 81.8 (4.3) 82.4 (4.1)
BMI (kg·m2) 25.7 (1) 26.2 (1)a 26.5(1.1) 26.7 (1.1)
P, placebo; T, testosterone.
Values are means (standard error of the mean).
aSigniﬁcantly different from baseline, P < 0.05.
Figure 2 Time course of changes in total testosterone. aSigniﬁcantly dif-
ferent from baseline, P < 0.05; bsigniﬁcantly different between two
groups, P < 0.05.
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0.0001, ICC = 0.81, ES = 0.47), Lf (7.1 ± 0.2 to 7.9 ± 0.2 cm,
95% CI = 7.9–8.2, P < 0.0001, ES = 0.84 vs. 7.7 ± 0.1 to 8.1
± 0.1 cm, 95% CI = 7.7–8, P < 0.0001, ES = 0.73), PA (20.0 ±
0.8 to 23.1 ± 0.7°, 95% CI = 21.2–22.6, P < 0.0001, ES = 1.2
vs. 17.0 ± 1.2 to 20.3 ± 0.9°, 95% CI = 20.7–22.1, P <
0.0001, ES = 0.88), and CSA of the quadriceps (61.4 ± 3.1 to
69.9 ± 2.6 cm2, 95% CI = 66.2–70.9, P < 0.0001, ES = 0.93
vs. 58.8 ± 4.1 to 64 ± 4.8 cm2, 95% CI = 62.9–67.7, P <
0.0001, ES = 0.41, ICC = 0.89). The majority of increases were
to a greater extent in the T group and with signiﬁcant differ-
ences between groups in MT (P=0.01), Lf (P=0.001), and CSA
(P=0.04) (Figure 4A–C).
Fibre-type cross-sectional area
Type I and IIa CSA increased in both the T and P groups
after RET (P < 0.05), but only T augmented type IIx (3455 ±
187 to 4576 ± 338 μm2, 95% CI = 3814–5659 vs. 3751 ± 478
to 3797 ± 767 μm2, 95% CI = 2560–4630, P = 0.02, ES =
0.64, Figure 5A–C).
Muscular performance
In line with higher levels of T (P < 0.0001, Figure 2), only the
T group showed a greater increase in static strength after
RET, for example, MVC at 70° (169.9 ± 9.6 to 209 ± 11.8
Nm, 95% CI = 11.5–66.6, P=0.002, ES = 1.3, Figure 6B) and
80° (169.4 ± 7.3 to 191.7 ± 12.5 Nm, 95% CI = 3.8–40.5,
P=0.01, ES = 1.01, Figure 6C) vs. baseline. Furthermore, dy-
namic strength (sum 1-RM across all six exercises) was aug-
mented into a greater extent in the T group vs. P (60.8 ±
3.6 vs. 43.25 ± 2.4%, 95% CI = T: 54.2–67.7 vs. P: 36.7–49.7,
P=0.0009, ES = 0.96, Figure 6A). There were similar increases
in speciﬁc strength (force per unit area) across the groups
(95% CI = T: 10.4–12.4; P: 10.1–11.9, ES = T: 0.88; P: 0.65, P
< 0.05, Figure 6D). Finally, FFM gains were correlated with
sum strength gains in the T study group but not in the P
group (Figure 6E).
Muscle protein synthesis and (extrapolated)
breakdown
There was a signiﬁcant difference in cumulative MPS
between T and P during RET (2.13 ± 0.21 vs. 1.34 ±
0.13%·day1, 95% CI = 1.7–2.4 vs. 1.1–1.8, P=0.0009, ES =
0.75), in line with ﬁndings of elevated FGR in T compared
with P (0.12 ± 0.02 vs. 0.03 ± 0.01%·day1, 95% CI = 0.07–
0.16 vs. 0.12 to 0.07, P=0.005, ES = 0.85) (Figure 7A and
7B). Furthermore, ASR was signiﬁcantly increased as a result
of RET in T (87.8 ± 5.1 to 148.5 ± 15.3 g·day1, 95% CI =
120–176, P=0.02, ES = 0.31) but not in P (84.7 ± 4.7 to 92.2
± 11.3 g·day1, 95% CI = 72–128, P > 0.05). In addition, esti-
mated ABR was signiﬁcantly higher in T than P during RET
(140.2 ± 15.8 vs. 90.2 ± 11.7 g·day1, 95% CI = 112–168 vs.
Figure 3 Muscle mass and body composition changes. (A–F) Values are means ± standard error of the mean. aSigniﬁcantly different from baseline, P<
0.05. FFM, fat-free mass; TFP, total fat percentage; TFM, total fat mass.
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70–126, P=0.02, ES = 0.55). Finally, when comparing ASR and
ABR, net protein turnover in the T group was higher than in
the P group (8.3 ± 1.4 vs. 1.9 ± 1.2 g·day1, 95% CI = 5.4–
11.2 vs. 0.9 to 4.8, P=0.004, ES = 0.86, Figure 7C–E). Using
D3–3-MH, there was no signiﬁcant difference in MPB be-
tween T and P at 6 weeks over the 4 h sampling period (T:
0.043 ± 0.012 vs. P: 0.032 ± 0.004 k·h1, P=0.5) (Figure 7F).
Muscle alkaline-soluble protein, DNA, and RNA
content
There were no changes in ASP or DNA concentrations per wet
weight muscle (μg·mg1) in T or P with RET; nonetheless, to-
tal RNA content (95% CI = T: 2.1–2.5; P: 1.6–2.1, P=0.002, ES =
0.78) and RNA:DNA ratio, a reﬂection of ribosomal capacity
for protein synthesis, only increased in the T group (95% CI
= T: 1.1–1.2; P: 0.7–1, P=0.002, ES = 0.83). Similarly, RNA:
ASP ratio, primarily a measure of ribosomal capacity,20 in-
creased in T (95% CI = 17.8–23.5, P=0.002, ES = 0.24) but
not in P (P=0.6, 95% CI = 15.2–20.9) over the RET phase. Fi-
nally, the ratio of ASP:DNA, a measure of cell size, did not
change in either group (Table 3).
Intramuscular signalling pathways
Acute exercise-induced anabolic signalling was quantiﬁed 60min
after the ﬁrst (0 week), ninth (3 weeks), and 18th (6 weeks) re-
sistance exercise sessions. We observed signiﬁcant increases in
the acute phosphorylation of AKTSer473 (95% CI = 2–4.2 vs. 0.7–
3, P=0.0006, ES = 0.66), mTORSer2448 (95% CI = 1.9–5.3 vs. 0.1–
3.3, P=0.001, ES = 0.0.64), MEK1/2Ser217/221 (95% CI = 1.1–3.6
vs. 0.1 to 2.5, P=0.02, ES = 0.43), MAPKAPK-2Thr334 (95% CI =
1.1–2.6 vs. 0.3–1.8, P=0.03, ES = 0.32), and RPS6ser240/244 (95%
Figure 4 (A–D) Fold change in muscle architecture. Values are means ± standard error of the mean. aSigniﬁcantly different from baseline, P < 0.05;
bsigniﬁcantly different between two groups, P < 0.05. CSA, cross-section area; Lf, fascicle length; MT, muscle thickness; PA, pennation angle.
Figure 5 (A–C) Time course of changes in ﬁbre-type cross-section area (CSA). Values are means ± standard error of the mean. aSigniﬁcantly different
from baseline, P < 0.05; bsigniﬁcantly different between two groups, P < 0.05.
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CI = 4.2–10.2 vs. 0.3–6.3, P=0.001, ES = 0.44) in T (6 weeks vs.
baseline) but not in P. In contrast to this, the P group increased
activation of AMPKαThr172 (95% CI = 1.5–3.4 vs. 1.8–3.6, P=0.02,
ES = 0.25) and RaptorSer792 (95% CI = 0.24–1.6 vs. 1.1–2.4,
P=0.01, ES = 0.84) after 6weeks RET. Furthermore, FoxO3aSer253
phosphorylation (P=0.01) was increased only after the ﬁrst exer-
cise bout in the P group. The relative abundance of MAFbx and
MURF-1 was unchanged throughout the study (Figure 8).
Figure 6 Time course of changes in (A) sum strength and (B–D) muscle strength and (E) correlation between fat-free mass (FFM) and sum strength.
Values are means ± standard error of the mean. aSigniﬁcantly different from baseline, P < 0.05; bsigniﬁcantly different between two groups, P < 0.05.
LM, legs fat-free mass; MVC, maximal voluntary contraction.
Figure 7 Muscle protein synthesis, fractional growth rate (FGR), absolute synthetic rate (ASR), absolute breakdown rate (ABR), and protein turnover.
Values are means ± standard error of the mean. aSigniﬁcantly different from baseline, P < 0.05; bsigniﬁcantly different between two groups, P < 0.05;
P < 0.11 Week 6 vs. baseline in testosterone group. FSR, fractional synthetic rate.
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Muscle gene expression
The expression of a number of genes involved in T metabo-
lism was augmented in T vs. baseline but not in the P group,
that is, androgen receptor (AR) (1.4 ± 0.1-fold change, 95% CI
= 1.2–1.5 vs. 0.84–1.2, P=0.01, ES = 0.71), Srd5a1 (1.6 ± 0.2-
fold change, 95% CI = 1.3–1.9 vs. 0.76–1.4, P=0.01, ES =
0.7), HSD17β3 (2 ± 0.4-fold change, 95% CI = 1.3–2.7 vs.
0.5–1.9, P=0.03, ES = 0.33), and AKRIC3 (2.1 ± 0.8-fold
change, 95% CI = 1.2–3.1 vs. 0.9–2.7, P=0.01, ES = 0.14, Figure
9A–D) increased after 6 week RET only in T. In addition, IGF-
1Ea (3.5 ± 0.07-fold change, 95% CI = 2.3–4.7 vs. 0.4–2.8, P <
0.0001, ES = 0.63) and IGF-1Ec (3 ± 0.4-fold change, 95% CI =
2.3–3.7 vs. 0.8–2.2, P < 0.0001, ES = 0.83) expression in-
creased only in T after 6 week RET (Figure 9E and 9F). While
mRNA expression of MHCI decreased in both groups (P <
0.05), the expression of MHCIIa was augmented only in T
(1.72 ± 0.3-fold change, 95% CI = 1.2–2.2 vs. 0.6–1.7,
P=0.02, ES = 0.33) (Figure 9G and 9H). T coupled with RET
augmented myogenesis-related gene expression, that is,
Myogenin (2.6 ± 0.7-fold change, 95% CI = 1.3–4.1 vs. 0.1–
2.7, P=0.02, ES = 0.53), C-Myc (7.2 ± 1.1-fold change, 95%
CI = 5.3–9.1 vs. 4.3–8.3, P=0.04, ES = 0.28), Myf-6 (3.9 ±
0.5-fold change, 95% CI = 3.1–4.7 vs. 1.1–2.8, P < 0.0001,
ES = 0.92), MEOX-2 (2.1 ± 0.4-fold change, 95% CI = 1.3–2.8
vs. 0.7–2.2, P=0.01, ES = 0.19), C-met (1.7 ± 0.1-fold change,
95% CI = 1.4–1.9 vs. 0.8–1.4, P=0.003, ES = 0.89) but not
PAX-7 (P> 0.05) as a marker of satellite cell proliferation (Fig-
ure 9I–N).
Mitochondrial oxidative phosphorylation capacity
Testosterone augmented mitochondrial transcription factor A
(Tfam) expression at 6 weeks (1.4 ± 0.2-fold change, 95% CI =
1.1–1.7 vs. 0.2–0.9, P=0.0002, ES = 0.91), whereas expression
of peroxisome proliferator-activated receptor-γ co-activator
1-α (PGC1-α) was increased only after the ﬁrst bout of exer-
cise (1.2 ± 0.2-fold change, 95% CI = 1.1–1.8 vs. 0.3–1.1,
P=0.037, ES = 0.7, Figure 10A and 10B). In addition to
increased mitochondrial density (assessed by relative change
of CS activity) in the T group (1.22 ± 0.07-fold change, 95% CI
= 0.9–1.4 vs. 0.7–1.1, P=0.03, ES = 0.29, Figure 10D), only the
T group showed enhanced protein levels of OxPhos complex
(C)-IV (95% CI = 1.2–2.6 vs. 0.3–1.7, P=0.02, ES = 0.41) and
V (95% CI = 0.9–2.2 vs. 0.1–1.3, P=0.04, ES = 0.23), while
there was a trend in C-II (P=0.08) but not in C-I (P=0.24) or
C-III (P=0.3) (Figure 10F–J). There was no impact of RET or T
therapy upon mtDNA copy number (P > 0.05, Figure 10E).
Discussion
There is a great deal of interest in identifying interventions
that will combat muscle wasting in older age. Herein, we elu-
cidated that just 6 week whole-body RET coupled with the ex-
ogenous provision of T had signiﬁcant positive effects on
FFM, and muscular performance via inducing net protein ac-
cretion through anabolic pathways, thus offsetting age-
related deﬁcits in adaptive responses to RET.20
The role of T in regulating muscle gains when coupled with
RET remains somewhat contentious. For instance, Ahtiainen
et al.44 reported that 12 month RET increased FFM without
altering endogenous T levels, concluding that changes in en-
dogenous T levels did not impact RET-induced muscular adap-
tations.44 However, in another study, suppression of
endogenous T using Zoladex blunted muscle adaptations to
8 week RET in younger men45, suggesting that endogenous
T levels are, at very least, permissive in regulating hypertro-
phic adaptations to RET. Therefore, given established links
between ageing and muscle loss, declines in T responses to
acute RE,20 and age-related anabolic resistance to RET,20 we
postulated that short-term T adjuvant to RET would be of
beneﬁt. Consistent with this thesis, it was previously reported
that exogenous T therapy adjuvant to RET for longer periods
(10–12 weeks) led to greater muscle mass gains46,47 than
with RET alone. Our present albeit shorter-term data also
showed that RET adjuvant to T led to signiﬁcant increases in
whole-body and appendicular FFM. Moreover, RET-induced
gains in MT, Lf, PA, and CSA in VL and quadriceps illustrate
Table 3 Muscle protein, RNA, DNA, and related ratios
Placebo Testosterone
Baseline Week 0 Week 3 Week 6 Baseline Week 0 Week 3 Week 6
ASP content (μg·mg1 ww) 110.5 (3.9) 108.5 (2.8) 107.4 (4.9) 106.9 (4.5) 118.2 (3.7) 115.3 (3.4) 118.2 (2.7) 118.5 (4.6)
RNA content (μg·mg1 ww) 1.6 (0.1) 1.8 (0.1) 2.1 (0.1) 1.9 (0.1) 1.7 (0.1) 2.1 (0.1) 1.8 (0.1) 2.3 (0.1)a
DNA content (μg·mg1 ww) 2.2 (0.1) 2.3 (0.1) 2.2 (0.1) 2.2 (0.1) 2.2 (0.1) 2.2 (0.1) 2.1 (0.1) 2.1 (0.1)
RNA:DNA (ratio) 0.7 (0.1) 0.7 (0.1) 0.9 (0.1) 0.8 (0.1) 0.7 (0.1) 0.9 (0.1) 0.8 (0.1) 1.1 (0.1)a
RNA:ASP (ratio) 15.3 (0.5) 17.1 (0.8) 19.9 (1.7) 18.1 (0.9) 14.6 (0.9) 17.8 (1.5) 15.5 (0.6) 20.7 (1.5)a
ASP:DNA (ratio) 50.7 (3.6) 46.1 (1.7) 49.2 (3.8) 47.9 (3.1) 54.2 (2.4) 52.6 (2.4) 56.5 (2.4) 56.6 (5.2)
ww, wet weight.
Values are means (standard error of the mean).
aSigniﬁcantly different from baseline, P < 0.05.
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that T therapy augmented local thigh muscle remodelling,
mainly by increasing Lf (number of sarcomeres in series48)
rather than increases in PA; remodelling also associated with
T-speciﬁc hypertrophy of type IIX ﬁbres. Previous studies in
younger adults have shown that the hypertrophic response
to T occurs in both slow and fast muscle ﬁbres49–51 (although
these studies were over longer periods). Considering previ-
ously described preferential loss of fast ﬁbres during age-
ing,52,53 our data suggest that exogenous provision of T to
healthy non-hypogonadal older men can be considered as a
therapy preventing atrophy—and perhaps loss—of these
muscle ﬁbres.
Figure 8 Intramuscular signalling pathways. Values are means ± standard error of the mean. aSigniﬁcantly different from baseline, P < 0.05;
bsigniﬁcantly different between two groups, P < 0.05.
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Because muscular performance is the culmination of neu-
ral and muscle structural elements and is the most important
attribute to maintaining mobility, we determined the role of
exogenous T in relation to aspects of muscle function. In
doing so, we established that the T group developed greater
static (MVC) and sum dynamic (1-RM) strength gains (in line
with greater muscle mass gains that strongly correlated with
strength improvement). Interestingly, previous work has
Figure 9 Muscle gene expression. Changes in testosterone and placebo in (A–D) testosterone metabolism gene expression, (E, F) anabolism, (G, H)
ﬁbre type, and (I–N) myogenic from baseline to Week 6. Values are means ± standard error of the mean. aSigniﬁcantly different from baseline, P <
0.05; bsigniﬁcantly different between two groups, P < 0.05.
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shown that there may be a neural component to the effects
of T, for example, inﬂuencing neurotransmitter synthesis,54
leading to reduced force ﬂuctuations55 and inducing recruit-
ment of larger/faster motor units (fast twitch ﬁbres).56 None-
theless, our MVC per LM ‘speciﬁc force’ data illustrate that
muscle mass gains were associated with strength-related im-
provements; given the strong correlation between FFM gains
and strength improvement in T group, we can thus conclude
that RET-induced FFM gains were a major component of im-
proved muscle performance in both groups. Physiological en-
dogenous T levels are correlated with RET-induced gain of
FFM and strength,57 perhaps explaining blunted adaptation
to RET in older vs. younger men.20,58 Dose–response studies
reported that higher doses (supra-physiological doses; i.e.
600 mg weekly) of T result in graded increments in FFM
and strength than lower doses (physiological doses) in men,
indicating that efﬁciency of the T therapy is associated with
the higher T doses.22,59,60 Thus, the ‘moderately’ supra-
physiological T levels61 in our study reveals that short-term
T supplementation was able to ‘overcome’ previously ob-
served anabolic resistance to RET20 in relation to muscle
growth. However, further studies are needed to fully address
the physiological vs. supra-physiological prerequisites to
efﬁcacy.
Figure 10 Mitochondrial oxidative phosphorylation capacity markers. Values are means ± standard error of the mean. aSigniﬁcantly different from
baseline, P < 0.05; bsigniﬁcantly different between two groups, P < 0.05.
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In order to assess the mechanisms underlying the ergo-
genic effects of T therapy adjuvant to RET in older men, we
for the ﬁrst time quantiﬁed cumulative rates of myoﬁbrillar
protein synthesis over the 6 weeks of RET. In doing so, we
demonstrated that T augmented MPS during RET while con-
comitantly increasing (estimated) FBR62 (which is supported
by the 3MH data) and crucially with net balance calculations
illustrating MPS > MPB. MPB is an important metabolic com-
ponent of muscle remodelling and protein turnover increase
with RET but to a lesser extent than MPS.63 The logical ex-
trapolation of a sustained increase in net muscle protein de-
position after RET is an increase in FFM and strength,5
entirely in line with our mass and strength gain data. Links be-
tween T and MPS have been previously established. For in-
stance, decreased muscle mass with castration-induced
androgen withdrawal suppressed myoﬁbrillar protein synthe-
sis in mice.64 In addition, 6 months11 and 4 weeks65 of T ad-
ministration increased MPS measured acutely in older men.
Further, T administration led to increases in MPS without
concomitant increases in inward amino acid transport,66 indi-
cating increased efﬁciency of reutilization of amino acids from
MPB with T.66 Interestingly, it was suggested that T adminis-
tration may improve net protein balance via decreasing MPB,
rather than an increasing MPS.67 However, we show that T
coupled to RET increased net protein accretion despite eleva-
tion of both MPS and MPB, because increases in MPS>MPB.
In order to explore the mechanisms underpinning in-
creases in MPS, we investigated aspects regulating the trans-
lational ‘efﬁciency’ of ribosomes68 corresponding to the
translational rate per ribosome.69 To evaluate this, we deter-
mined acute RE-induced phosphorylation within MAPKAPK-2
(target of MAPK pathway), MEK1/2 (upstream components
in ERK1/2 cascade),70 and mTORC120 pathways, across the
duration of the 6 week RET. It is noteworthy from past work
that activation of many of these pathways is blunted in older
age20,70,71 and that in the present study, T administration
could reverse these impairments. Consistently, there is a gen-
eral blunted activation of mTORc1,71 ERK1/2,70 and MAPKs70
presumably due to lesser bioavailability of T.64,72 In support
of this, T therapy augmented IGF-1/Akt/mTOR signalling ac-
tivity (which regulates MPS64), presumably explaining en-
hanced mass and functional gains and suggesting that T
levels, at least permissively, regulate muscle adaptations. In
addition to increases in translational efﬁciency, another facet
that is blunted with age20 and potentially impacts ‘capacity’
for increasing protein synthesis and net protein balance and
is critical for anabolic potential and hypertrophy is ribosomal
RNA content.73 In the present study, exogenous T therapy
coupled with RET increased total RNA content per ‘cellular
unit’ (RNA:DNA ratio), an indicator of ribosomal abundance,74
and total RNA:ASP ratio, as an index of synthetic capacity,
thereby offsetting age-related deﬁcits.75 Although we ob-
served only subtle (non-signiﬁcant) increases in ASP:DNA ra-
tio, an indicator of myonuclear domain size,74 despite there
being robust increases in muscle mass (DXA, ultrasound,
and histology), this is to be expected because of the mainte-
nance of the myonuclear domain size beyond which addi-
tional hypertrophy can only be realized by addition of
myonuclei.68
No study has previously examined the effect of RET adju-
vant to T in relation to muscle steroid-metabolism handling
in older human muscle. In our study, T therapy augmented
AR mRNA and steroidogenic enzyme expression perhaps
resulting in higher muscle T processing capacity, presumably
due to inﬁltration of T from the circulation76 and processing
by 5-α reductase. Furthermore, the AR77 not only alters
mRNA expression of thousands of target genes 78 but also is
associated with ﬁbre-type CSA increases,79 as well as trigger-
ing anabolic kinase signalling, that is, ERK, PI3K, and Akt,72
suggesting transcriptional links to augmented MPS, FFM,
and strength in the T group in the present study and
others.26,79–81 In addition to increases in T metabolism-
related mRNA expression, we demonstrated that myogenic
and growth factor-related gene expression was enhanced
with T. Speciﬁcally, IGF-1Ec up-regulation is purported to cor-
relate with transcriptional activity82 and initiation of satellite
cell proliferation,83 while IGF1-Ea expression is correlated
with increased translation82 and promotion of myogenic dif-
ferentiation.83 Both intramuscular IGF-1 and T independently
stimulate AR and thereafter expression of other anabolic
genes72,77,78; therefore, it is highly likely that an IGF-1 signal-
ling axis played a role in the efﬁcacy of T therapy. Here, we
also show augmented expression of myogenic regulatory fac-
tors (MRFs) and fast ﬁbre-type-speciﬁc mRNA expression (i.e.
MHCIIa expression83) in line with fast ﬁbre, lower body, and
whole-body hypertrophy with T. This supports previous
work77,84 demonstrating a pro-myogenic role for T; for exam-
ple, T increased the transformation of pluripotent precursor
cells down the myogenic lineage. It has been shown that sin-
gle bouts of RE or short-term RET are sufﬁcient to increase
the abundance of MRFs mRNA species in young partici-
pants.73,76 However, in the present study, in line with past
work in older age,83,85 in the P group, these regulatory genes
did not change either after an acute bout of RE or after 6
week RET with the exception of C-myc (which controls cell
growth and ribosomal biogenesis20). We speculate this con-
tributed to blunted adaptations to RET in P20 while helping
explain greater muscle mass accretion with T therapy.
In addition to declines in muscle mass and function with
age, muscle mitochondria are also subject to age-related re-
modelling. For instance, it was reported that ageing is associ-
ated with decreases in PGC1-α mRNA (a main regulator of
mitochondrial biogenesis and oxidative capacity86), OxPhos
capacity, mitochondria enzyme activity (e.g. CS), mtDNA con-
tent, and increases in oxidative stress, which all result in an
impaired mitochondrial function87. Crucially, exercise, includ-
ing RET, is known to induce mitochondrial adaptations. For in-
stance, 12 week RET augmented mitochondrial content,88
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volume,89 and respiratory capacity,90 in younger participants.
Further, 6 month RET increased mitochondrial mass in older
women91 and mitochondrial function/transcriptome activity
in older men.92 As we showed in our P study group, short-
term RET did not augment mitochondrial CS activity in older
men; but similar to short-term (i.e. 7–9 weeks) endurance
training adjuvant to T therapy in mice,93,94 we showed RET
coupled to T therapy augmented PGC1-α/Tfam mRNA, mito-
chondrial CS activity,2 and protein levels of complex IV (cyto-
chrome c oxidase subunit85) and V (ATP synthase subunit)85
(not mtDNA copy number). Possible mechanisms include
heightened activation of IGF-1/MAPK pathways87,95 and aug-
mented MRFs mRNA (e.g. Myogenin)96 during RET, as ob-
served in the T study group, which consequently mediate
mitochondrial gene expression.87,96 Furthermore, because
mitochondrial gene expression (i.e. PGC1-α) is regulated by
Akt/mTOR signalling,97,98 which were all up-regulated with
T, this may also explain our observations of greater CS activity
with adjuvant T therapy. Moreover, sustained muscle growth
and MPS during RET in the T group likely required greater in-
creases in mitochondrial function or volume due to the in-
creased energy demands of intracellular protein accretion.89
Previous work has also shown that the AR98 and systemic
levels of T were positively associated with cytochrome c oxi-
dase,98,99 CS100 activity, and mitochondrial protein synthesis,
in addition to Tfam and PGC1-α expression,98 culminating in
enhanced mitochondrial biogenesis and respiratory capacity
and function.99 Conversely, AR and T deﬁciency has been as-
sociated with lower levels of PGC1-α expression101 resulting
in decreases in OxPhos capacity.102 In summary, greater
MPS, myoﬁbrillar protein accretion, and consequent muscle
hypertrophy alongside greater mitochondrial adaptations2 in
the T therapy group demonstrate the efﬁcacy of adjuvant T
in yielding positive hypertrophic and energetic adaptations.
We conclude that administration of T coupled to RET is an
effective short-term (6 weeks) intervention to overcome age-
related deﬁcits in the responsiveness of older muscle to RET.
Short-term RET adjuvant to T was also well tolerated and
could be useful as both pre-habilitation and rehabilitation in-
terventions in elective surgery and other clinical procedures
in older populations. Nevertheless, it is important to be cog-
nizant of potential adverse effects. T therapy has been asso-
ciated by (non-signiﬁcant) increases in some disorders, for
example, cardiovascular risk103 and/or prostate hypertro-
phy.104 While randomized controlled trials have been
insufﬁciently powered to detect differences in the rates of
adverse events,105 some have reported an increased risk of
stroke and/or myocardial infarction,106 whereas others have
reported to be uncertain of such effects.105,107–109 No ad-
verse events were noted during or after completion of the
present study in older men and a major beneﬁt of our ap-
proach is the short-term efﬁcacy of therapy. Finally, we reveal
the likely mechanisms underlying the effect of T therapy in
relation to ‘overcoming’ aspects of age-related anabolic resis-
tance, vis-à-vis, elevating protein turnover (with greater in-
creases in MPS), enhancing translational efﬁciency and
capacity, and inducing pro-myogenic and T handling gene reg-
ulation. Given links between declining T and muscle ageing in
women,110 similar studies in women are likely to deliver sim-
ilar beneﬁts. Short-term T administration may have a role in
the treatment of frailty in older men without inducing any ad-
verse side effects; however, older men receiving T therapy
should be carefully monitored because of its potential risks.
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